Concurrent e-cigarette or vaping product use-associated lung injury (EVALI) and myopericarditis: a rare case report and literature review Authors: Hanh-Duyen Bui-Thi, Quoc-Khanh Tran-Le, Anh Huynh-My, Kien Phan-Trung, Lan Le-Thi-Tuyet, Thao Thi Ngoc Pham Published: 2025 ABSTRACT AbstractBackgroundWith the rise in vaping both in Vietnam and globally, acute complications related to vaping are becoming increasingly recognized. Although lung injury is the most common clinical presentation, instances of cardiac damage, including pericardial involvement, albeit less frequently, have also been reported. We describe what is, to our knowledge, the first reported instance of an adolescent who developed acute respiratory distress syndrome and myopericarditis in temporal association with vaping.Case presentationA previously healthy 17-year-old male resumed heavy e-cigarette use three days before experiencing sudden pleuritic chest pain and dyspnoea. On admission, he rapidly progressed to hypoxaemic respiratory failure requiring mechanical ventilation and vasopressor support. Chest X-ray bilateral opacities, consistent with EVALI. Transthoracic echocardiography revealed a circumferential pericardial effusion (up to 14 mm) without ventricular dysfunction. Cardiac biomarkers were markedly elevated. Diagnosed with e-cigarette, or vaping-associated lung injury (EVALI) and myopericarditis, lung-protective ventilation, intravenous methylprednisolone and empiric broad-spectrum antibiotics were instituted. The patient responded well to the corticosteroid treatment. Follow-up imaging confirmed near-complete resolution of pulmonary infiltrates and complete resolution of the pericardial effusion. He has remained asymptomatic at three-month review after counselling to cease vaping. A review of the literature on acute cardiac complications associated with e-cigarettes suggests that these complications may be underrecognized.ConclusionsThis case highlights that vaping-related injury can extend beyond the lungs, eliciting simultaneous fulminant pulmonary and cardiac inflammation. Clinicians should maintain a high index of suspicion for EVALI and associated extrapulmonary issues like myopericarditis in young patients presenting with acute cardiorespiratory failure following e-cigarette use and should obtain a detailed vaping history to guide timely diagnosis and corticosteroid therapy.Keywords: E-cigarettes, EVALI, Lung injury, Myopericarditis, Vaping Background E-cigarette use has risen sharply in Vietnam and worldwide, especially among young people [1, 2]. As vaping becomes more common, clinicians are reporting a broader spectrum of acute complications. Lung injury, termed e-cigarette or vaping-associated lung injury (EVALI), is now well documented [3, 4], but cardiac involvement has received less attention. In this study, we present a case of a young adult diagnosed with concurrent EVALI and myopericarditis after vaping. The patient responded well to the corticosteroid treatment. By comparing this presentation with previously published cases of vaping-related cardiac injury, we highlight that acute pericardial and other cardiac complications may be underrecognized consequences of e-cigarette use. Case presentation A 17-year-old male patient with no previous medical illness presented to the emergency department of a secondary-level provincial hospital with sudden-onset, non-radiating chest pain and dyspnoea that began while he was doing laundry. He had smoked approximately one pack of cigarettes per day for 2.5 years (2.5 pack-years) and had been an intensive vaper for 4 years before quitting one year ago, typically consuming one bottle of e-liquid every 4–5 days. Since then, he experienced occasional cravings, leading to brief relapses of e-cigarette use every 2–3 months. According to the patient and his parents, he had resumed intensive vaping three days prior to symptom onset, vaping three to four times per day and consuming a 30 mL bottle of e‑liquid over two days. The product used was identified as a salt nicotine e-liquid with a labeled concentration of 30 mg/mL (3%) with green apple flavoring. The base is presumed to be a mixture of propylene glycol and vegetable glycerin; however, the manufacturer does not provide a full ingredient list, leaving the presence of other additives unknown. Additionally, after repeated investigations by both his parents and the patient, there is no evidence that he used tetrahydrocannabinol (THC)-containing products. Within 24 h of arrival, the patient developed progressive hypoxaemic respiratory failure. Oxygen delivered via a non-rebreather mask at 15 L/min maintained his SpO₂ at only 90%, while his respiratory rate rose to 34 breaths/min. He was therefore switched to high flow nasal cannula therapy at 60 L/min with an FiO₂ of 1.0. After six hours of maximal setting high-flow nasal cannula, SpO₂ remained below 90% and the work of breathing worsened, necessitating endotracheal intubation and lung protective mechanical ventilation. The patient also developed persistent hypotension, requiring vasopressor support with noradrenaline. Because of his critical state, he was transferred to the Intensive Care Unit (ICU) of our tertiary-level university medical centre. Admission blood tests revealed leukocytosis (20.4 × 103/µL) with neutrophils at 17.02 × 103/µL, lymphocytes at 1.76 × 103/µL, and eosinophils at 0.39 × 103/µL. The D-dimer level was elevated at 3109 ng/mL. Inflammatory markers were markedly elevated (interleukin-6 237 pg/mL, C-reactive protein 120 mg/L); procalcitonin rose from 0.2 to 8.8 ng/mL after hemodynamic deterioration. Cardiac enzymes revealed a troponin-I peak of 1485 ng/L without a significant secondary rise, and NT-proBNP reached 13,908 pg/mL. Creatinine level was 1.2 mg/dL on admission. Arterial blood gas analysis on Day 1 demonstrated severe hypoxemia with PaO₂ of 46 mm Hg while receiving FiO₂ of 0.70 (PaO₂/FiO₂ (P/F) ratios of approximately 65 mm Hg). There were no clinical signs of adrenal insufficiency or thyroid dysfunction; thyroid tests were within normal limits (TSH 2.1 mIU/L; free T4 1.2 ng/dL), and the patient had no history of corticosteroid use. Chest X-ray (CXR) showed bilateral infiltrates. No pulmonary embolism was detected. Transthoracic echocardiography revealed a left-ventricular ejection fraction of 57% and a circumferential pericardial effusion measuring up to 14 mm, with no regional wall-motion abnormalities, signs of right ventricular failure, or significant pulmonary hypertension. A thorough microbiological examination was conducted, with diagnostic tests including blood cultures, tracheal aspirate analysis (involving Gram stain, culture, and acid-fast bacillus (AFB) stain), and a FilmArray® Respiratory Panel performed on Day 2 to identify pneumonia-causing bacteria (including atypical species), antimicrobial resistance genes, and respiratory viruses. HIV serology and polymerase chain reaction (PCR) for Pneumocystis jirovecii from the tracheal aspirate were also conducted. All results were negative, except the FilmArray® panel, which identified Acinetobacter baumannii at 10⁴ CFU/mL harboring the resistance genes CTX-M and KPC. Antinuclear antibodies and antineutrophil cytoplasmic antibodies were negative. Given the clinical presentation, imaging findings and the link between the resumption of e-cigarette use three days prior and symptom onset, a diagnosis of EVALI and myopericarditis was made. The patient was mechanically ventilated according to the Acute Respiratory Distress Syndrome (ARDS) lung protection protocol, which included high PEEP, low tidal volume ventilation, deep sedation, and muscle relaxation. Intravenous methylprednisolone 1 mg/kg/day was given for 5 days, then tapered. Given the potential for community-acquired pneumonia, the patient received empirical treatment with meropenem and vancomycin. Colistin was subsequently initiated based on the FilmArray® panel result but was stopped after Day 5. On Day 3, PaO₂ had risen to 174.6 mm Hg on FiO₂ 0.40 (P/F ratio of approximately 436 mm Hg), allowing for stepwise reduction of ventilatory support and eventual extubation on Day 5. Chest radiographs showed corresponding improvement. Renal function recovered, with creatinine improving from 1.2 mg/dL to 0.78 mg/dL on day three. He was transferred to the pulmonary ward and discharged home on Day 9. He was counselled to avoid further e-cigarette use and scheduled for serial follow-up of lung and cardiac function. Follow-up chest radiography showed near-complete resolution of infiltrates (Fig. 1), and repeat echocardiography confirmed disappearance of the pericardial effusion. Chest radiographs (CXR) at admission (A), day 3 (B), and day 7 (C). A Initial CXR showed bilateral infiltrates and a globally enlarged cardiac silhouette, consistent with pericardial effusion. (B, C) Follow-up CXR demonstrated resolution of the infiltrates, although pericardial effusion persists Discussion and conclusions This report details a critical case of EVALI and myopericarditis in a previously healthy 22-year-old man who resumed vaping three days before admission. This concurrence highlights the vaping’s capacity to trigger severe, multi-system inflammatory reactions that extend well beyond the lung. Such cases are particularly concerning given the documented rise in e-cigarette use globally, especially among adolescents and young adults. The global prevalence of e-cigarette use has increased substantially over the past decade. While precise figures vary, estimates by Jerzynski et al. suggest tens of millions of users worldwide [2]. This trend is particularly pronounced among youth in many countries. In Viet Nam, where commercial sales remain illegal, surveys nevertheless show a jump in youth ever-use from 0.2% in 2015 to 3.6% in 2020, with even higher prevalence (around 8%) reported in some large cities [4]. Easy access via online markets and cross-border smuggling blunts the effect of current regulations and heightens the public-health stakes of acute complications such as those in the present case. EVALI diagnosis relies on clinical presentation, characteristic imaging findings (often bilateral ground-glass opacities), exclusion of infectious etiologies, and, importantly, a documented history of vaping within 90 days of symptom onset (diagnostic criteria are presented in Table 1) [5]. In this case, the young patient was presented with severe chest pain, progressive respiratory failure, and bilateral extensive infiltrates within 72 h of vaping resumption. The close temporal association and negative infectious evaluation support EVALI as the leading diagnosis. A. baumannii was isolated at 10⁴ CFU/mL from an endotracheal aspirate obtained at around the 48-hour mark after intubation. Given the timing when airway colonization is common and the rarity of community-onset A. baumannii pneumonia in immunocompetent adolescents, this likely represented colonization rather than true infection [6]. The patient’s rapid clinical and radiographic improvement after corticosteroid therapy, despite early discontinuation of targeted anti‑Acinetobacter antibiotics on day 5, further supports a non‑pathogenic role for this organism in the present case. Table 1Definitions of confirmed and probable cases of e-cigarette or vaping product use–associated lung injury as defined by the U.S. Centers for disease control and prevention 2019 [5]Confirmed Case• E-cigarette use in 90 d before symptom onset AND• Pulmonary infiltrate, such as opacities, on plain film chest radiograph or ground-glass opacities on chest CT AND• Absence of pulmonary infection on initial work-up. Minimum criteria are: ▪ A negative respiratory viral panel ▪ A negative influenza PCR or rapid test, if local epidemiology supports influenza testing ▪ All other clinically indicated respiratory infectious disease testing (e.g., urine antigen for Streptococcus pneumoniae and Legionella, sputum culture if productive cough, BAL culture if done, blood culture, HIV-related opportunistic respiratory infections if appropriate) are negative AND• No evidence in medical record of alternative plausible diagnoses (e.g., cardiac, rheumatologic, or neoplastic process)Probable Case• E-cigarette use in 90 d before symptom onset AND• Pulmonary infiltrate, such as opacities, on plain film chest radiograph or ground-glass opacities on chest CT AND• Infection identified via culture or PCR, but clinical team‡ believes this infection is not the sole cause of the underlying lung injury OR minimum criteria to rule out pulmonary infection not met (testing not performed) and clinical team‡ believes infection is not the sole cause of the underlying lung injury AND• No evidence in medical record of alternative plausible diagnoses (e.g., cardiac, rheumatologic, or neoplastic process)BAL bronchoalveolar lavage, CDC U.S. Centers for Disease Control and Prevention, COVID-19 coronavirus disease, CT computed tomography, HIV human immunodeficiency virus, PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2† This would include exclusion of COVID-19 infection since the emergence of the SARS-CoV-2 pandemic‡ Clinical team caring for the patient Definitions of confirmed and probable cases of e-cigarette or vaping product use–associated lung injury as defined by the U.S. Centers for disease control and prevention 2019 [5] BAL bronchoalveolar lavage, CDC U.S. Centers for Disease Control and Prevention, COVID-19 coronavirus disease, CT computed tomography, HIV human immunodeficiency virus, PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 † This would include exclusion of COVID-19 infection since the emergence of the SARS-CoV-2 pandemic ‡ Clinical team caring for the patient The patient’s shock etiology was evaluated systematically. Endocrine causes (adrenal insufficiency and thyroid dysfunction) were unlikely based on clinical assessment and lab results, narrowing the differential to distributive, cardiogenic, and obstructive shock. Echocardiography showed normal biventricular function and a moderate pericardial effusion without tamponade, making cardiogenic and obstructive shock unlikely. The remaining diagnosis was distributive shock, either septic or non-infectious inflammatory. The profound inflammatory state was evidenced by markedly elevated markers (IL-6 237 pg/mL; CRP 120 mg/L). Given the negative culture results and the rapid resolution of lung injury after initiation of methylprednisolone, the treating physician discontinued antibiotic therapy after five days. Septic shock was considered unlikely, as the patient’s hemodynamic status remained stable following early cessation of antibiotics. Overall, the presentation is most consistent with a severe, nonseptic, inflammation-mediated distributive shock characterized by vasodilation and capillary leak. This case raises concerns about the potential cardiovascular impact of e-cigarette use, including myopericarditis and vasodilation, mediated by systemic inflammation. The pathophysiology of EVALI remains incompletely defined. Current data implicate multiple inhaled toxicants: nicotine; propylene glycol (PG); vegetable glycerin (VG); vitamin E acetate (VEA); tetrahydrocannabinol (THC); and various flavoring agents. The inhalation of aerosolized VEA can cause pulmonary inflammation, as demonstrated in animal models [7, 8] and clinical observations, with high concentrations of VEA found in the bronchoalveolar lavage of EVALI patients [9]. Pulmonary inflammation and oxidative stress can also result from nicotine [10], PG, and VG [11–13]. Additionally, the generation of respiratory toxicants that damage the alveolar structure can result from the thermal degradation of PG, VG [14], and VEA [15, 16]. These solvents can disrupt pulmonary surfactant, increasing surface tension and potentially leading to lung atelectasis [17, 18]. Concurrent with severe lung injury, our patient presented with myopericarditis, evidenced by chest pain, markedly elevated troponin I and NT-proBNP levels, and moderate pericardial effusion on echocardiography with no left ventricular dysfunction, meeting the standard diagnostic criteria for myopericarditis [19]. Our patient adds to a small but growing body of literature of acute vaping-related cardiac complications. We conducted a focused review of the literature to further clarify the incidence of cases presenting with acute cardiac complications associated with e-cigarette use (Table 2). A total of 26 cases of vaping-related cardiac complications, including our own. Of these, the majority of patients were male (20 of 26, 76.9%) with a median age of 22 years (range: 13–48 years). This suggests a significant male predominance and a particular vulnerability among adolescents and young adults. In this cohort, 4 deaths have been recorded, corresponding to an overall case-fatality rate of approximately 1%, showing that vaping-induced cardiac injury carries a clinically meaningful risk of mortality. Table 2Literature review of acute cardiac complications associated with e-cigarette useNoStudyYearCountryGenderAgeALIElevated TroponinLeftventricular dysfunctionCardiac involvementVaping durationSubstance(s)TreatmentOutcome1Akkanti et al. [20]2020USAMale27+NS+Pericarditis, biventricular systolic dysfunction2 yearsTHC, Vitamin E acetateSteroids, VA-ECMODied2Sayeedi et al. [21]2020USAMale18+NSNSCardiac arrestNSNSSteroids, MVSurvived3Thakrar [22]2020USAMale16+NSNSPericardial effusionNSNicotineDrainageSurvived4Thakrar [22]2020USAMale16+NSNSPericardial effusionNSNicotine, THCDrainageSurvived5Schekochikhina et al. [23]2021USAFemale35+-NSCardiac arrestRecent switch*NSSteroids, MVSurvived6Ali et al. [24]2021USAMale47+-NSSTEMI (proximal LAD occlusion)NSNSPrimary PCISurvived7Amirahmadi et al. [25]2021USAFemale19+++Reversible cardiomyopathy (EF 35–40%)3 yearsNicotine, THCBiPAP, steroidsSurvived8Abusharekh et al. [26]2021TurkeyMale37+++STEMI4 months†Nicotine e-cigarettePrimary PCISurvived9Glenski et al. [27]2021USAMale13-NSNSSudden arrest (VF/VT) with anomalous LCANSNicotineCPR, defibrillation, LCA unroofingSurvived10Seri et al. [28]2022USAMale48---Brugada pattern, VF, sudden cardiac arrest8 yearsTHCDefibrillation, lidocaine, ICDSurvived11Maharaj et al. [29]2022Trinidad and TobagoMale31---Pericardial Effusion2 monthsTHCAspirin, colchicineSurvived12Kwack et al. [30]2023KoreaMale34+NSNSPericardial effusionNot ReportedNicotineSteroidsSurvived13McClelland [31]2021USAMale21+-+Constrictive pericarditis6 yearsTHC, NicotineNSAIDs, colchicine, steroids, pericardiectomySurvived14McMillan et al. [32]2023USAMale17+NS+Pulmonary embolism, pulmonary hypertension3 yearsTHC, NicotineAnticoagulation, VA-ECMO, thrombolysis, thrombectomySurvived15Schuh et al. [33]2023USAMale20-++PerimyocarditisNSNSNSAIDs, colchicine, steroidsSurvived16Tran Duc Minh et al. [34]2023VietnamMale27-+-Pericarditis2 daysNSNSAIDs, colchicineSurvived17Brennan et al. [35]2023USAMale35+++Cardiomyopathy (HFrEF)NSNicotine (likely)Steroids, GDMT for HFrEFSurvived18Ahmed et al. [36]2024USAFemale22---Cardiac arrest (VT followed by VF)1 yearNon-nicotineDefibrillation, amiodarone, esmolol, heparinSurvived19Bains et al. [37]2024USAMale19-NSNSSudden cardiac arrest (VF)3 weekNicotine (likely)CPR, defibrillation, ICD, beta-blockerSurvived20Bains et al. [37]2024USAMale19-NSNSSudden cardiac arrest (VF)1 yearNSCPR, defibrillation, ICD, beta-blockerSurvived21Bains et al. [37]2024USAFemale21-NSNSSudden cardiac arrest (VF) with CPVT12nd sessionNSCPR, defibrillation, prior therapy for CPVT1Survived22Bains et al. [37]2024USAFemale31-NSNSVT with prolonged QT (LQTS genotype)NSNSCPR, defibrillation, LCSD, pacemakerSurvived23Bains et al. [37]2024USAFemale19-NSNSSudden cardiac arrest10 weeksNicotine (JUUL device)NoneDied24Bains et al. [37]2024USAMale26+NSNSFocal interventricular septal hemorrhage3 monthsNicotine, THCCPRDied25Fernandez et al. [38]2024PhilippinesMale22+++Anteroseptal ST-elevation myocardial infarction2 yearNSSteroids, PCI, MVDied26Present study2024VietnamMale17++-Myopericarditis4 years‡NicotineSteroids, MVSurvivedAbbreviations: + Positive/Present, – Negative/Absent, ALI Acute Lung Injury, BiPAP Bilevel Positive Airway Pressure, CPVT1 Catecholaminergic Polymorphic Ventricular Tachycardia Type 1, CPR Cardiopulmonary Resuscitation, ECMO Extracorporeal Membrane Oxygenation, EF Ejection Fraction, GDMT Guideline-Directed Medical Therapy, HFrEF Heart Failure with Reduced Ejection Fraction, ICD Implantable Cardioverter-Defibrillator, LAD Left Anterior Descending Artery, LCA Left Coronary Artery, LCSD Left Cardiac Sympathetic Denervation, LQTS Long QT Syndrome, MV Mechanical Ventilation, NS Not specified, NSAID Non-steroidal Anti-inflammatory Drug, PCI Percutaneous Coronary Intervention, STEMI ST-Elevation Myocardial Infarction, THC Tetrahydrocannabinol, USA United States, VA Veno-arterial, VF Ventricular Fibrillation, VT Ventricular Tachycardia* Switched from conventional cigarettes after 11 years† Following a 10 pack-year history of conventional smoking‡ Habitual use for 4 years with intensive relapse 3 days before admission Literature review of acute cardiac complications associated with e-cigarette use Abbreviations: + Positive/Present, – Negative/Absent, ALI Acute Lung Injury, BiPAP Bilevel Positive Airway Pressure, CPVT1 Catecholaminergic Polymorphic Ventricular Tachycardia Type 1, CPR Cardiopulmonary Resuscitation, ECMO Extracorporeal Membrane Oxygenation, EF Ejection Fraction, GDMT Guideline-Directed Medical Therapy, HFrEF Heart Failure with Reduced Ejection Fraction, ICD Implantable Cardioverter-Defibrillator, LAD Left Anterior Descending Artery, LCA Left Coronary Artery, LCSD Left Cardiac Sympathetic Denervation, LQTS Long QT Syndrome, MV Mechanical Ventilation, NS Not specified, NSAID Non-steroidal Anti-inflammatory Drug, PCI Percutaneous Coronary Intervention, STEMI ST-Elevation Myocardial Infarction, THC Tetrahydrocannabinol, USA United States, VA Veno-arterial, VF Ventricular Fibrillation, VT Ventricular Tachycardia * Switched from conventional cigarettes after 11 years † Following a 10 pack-year history of conventional smoking ‡ Habitual use for 4 years with intensive relapse 3 days before admission The literature review indicates that vaping damages the myocardium through multiple, overlapping pathways. Published reports now span a continuum of phenotypes: mild inflammatory disorders (pericarditis, myopericarditis); ischemic injury (ST-segment–elevation myocardial infarction attributed to plaque destabilization); new-onset cardiomyopathy with reduced ejection fraction; thromboembolic events (pulmonary embolism with secondary pulmonary hypertension); and malignant ventricular arrhythmias, including ventricular fibrillation, ventricular tachycardia, Brugada patterns, and marked QT prolongation. Recent cases, such as those of Bains et al. [37], further expand this spectrum, documenting clusters of sudden cardiac arrest in previously healthy young adults. In several of these cases, the arrest unmasked latent channelopathies such as catecholaminergic polymorphic ventricular tachycardia or long-QT syndrome, underscoring vaping’s potential to precipitate acute electrical instability in genetically susceptible individuals [37]. Notably, approximately 38.5% of documented vaping-associated cardiac injuries (10/26 cases) occurred without concurrent pulmonary involvement. This pattern implies two, not mutually exclusive, mechanisms: (i) certain e-cigarette constituents exert direct cardiotoxic effects; (ii) distinct constituents or exposure profiles preferentially damage either the lungs or the heart. Vaping is known to raise heart rate and blood pressure, provoke vasoconstriction, impair endothelial function, and enhance oxidative stress and systemic inflammation [39, 40]. Nicotine’s sympathomimetic action alone can drive adverse cardiac remodeling and endothelial injury [41]. In addition, various e-liquid flavorings, such as cinnamon and menthol, direct endothelial toxicity, capable of causing DNA damage, inducing cell death, increasing oxidative stress, and impairing angiogenesis, further contributing to endothelial dysfunction and promoting pro-inflammatory, injury-prone milieu [42]. Additionally, the clustering of sudden cardiac arrest (SCA) suggests vaping may act as an environmental trigger for latent arrhythmic disorders. Nicotine and other e-cig constituents directly disrupt cardiac repolarization by blocking potassium channels [43], provoking changes in ventricular repolarization [44], and triggering ventricular arrhythmias in experimental models [45, 46]; or cause vaping-induced lung injury can unleash a cytokine surge (e.g., IL-6) that prolongs the QT interval and destabilizes cardiac rhythm [47, 48]. Together, these direct electrophysiologic effects and indirect, inflammation-mediated effects likely contributed to the SCA events observed [37]. Our patient mirrors the prototypical case: a male adolescent with combined pulmonary and cardiac inflammation. However, he is distinguished by preserved systolic function (LVEF 57%) and rapid resolution of both lung infiltrates and pericardial effusion after corticosteroid therapy. This contrasts with reduced-EF cases (e.g., Akkanti et al. [20], Amirahmadi et al. [25], McMillan et al. [32], Brennan et al. [35], Fernandez [38]) and demonstrates that myocardial involvement can occur without overt ventricular dysfunction. The absence of left-sided failure and the rapid resolution of both lung infiltrates and pericardial effusion after corticosteroid therapy in our patient support an inflammatory, rather than ischemic, mechanism, potentially driven by cytokine-mediated responses to inhaled toxins. These findings have significant clinical implications. Given that cardiac injury can manifest without overt respiratory symptoms, physicians should maintain a high index of suspicion for cardiac involvement in patients with a history of vaping. It is alarming that troponin levels were not specified in 50.0% of the reviewed cases (13 of 26), and left ventricular function was not mentioned in 38.5% (10 of 26). This suggests potential under-recognition and under-investigation of myocardial injury in patients presenting with vaping-related symptoms, possibly due to a historical focus on pulmonary manifestations during the 2019 EVALI outbreak. A thorough cardiovascular investigation should include cardiac biomarkers (e.g., troponin and NT-proBNP), electrocardiography to detect arrhythmias or ischemic changes, and imaging such as echocardiography or cardiac magnetic resonance imaging to assess for effusion, dysfunction, or inflammation. In terms of management, systemic corticosteroids are widely used for the profound inflammatory state in both EVAL, despite the absence of randomized controlled trials, as multiple reports describe rapid clinical and radiological improvement following their administration for EVALI [4, 49]. For vaping-related cardiac complications, corticosteroids were the most common intervention (11/26 cases, 42.3%) and associated with favorable outcomes in most instances, including rapid inflammation resolution as in our patient. Other anti-inflammatory therapies, such as NSAIDs and colchicine, are generally effective for inflammatory myopericarditis [19]. However, two fatal cases (Akkanti et al. [20] and Fernandez et al. [38]) involved corticosteroids, highlighting that steroids alone may not suffice in severe, multi-organ presentations. It is important to contextualize the risks highlighted by this case in the broader public-health debate on e-cigarettes. While some observational studies suggest lower cardiovascular risk with e-cigarettes than with combustible tobacco [50, 51], significant concerns remain. A major concern is the documented surge in e-cigarette uptake, particularly among young people who might not otherwise have initiated nicotine use [52]. Furthermore, as illustrated by cases like ours and the EVALI epidemic, severe adverse effects can manifest acutely in the user’s experience, contrasting with the longer-term development of many traditional smoking-related diseases. More importantly, acute cardiac complications from e-cigarette use may be significantly under-recognized due to a lack of clinical awareness or diagnostic oversight. This underrecognition can lead to delayed diagnosis and suboptimal management. Recognizing these risks, some authorities have implemented stringent regulatory measures. For example, starting in 2025, Vietnam has banned the sale and distribution of e-cigarettes [53], reflecting the urgency of tackling vaping-related health threats. In conclusion, this case highlights the potential for e-cigarette use to be temporally associated with life-threatening, concurrent pulmonary and cardiac inflammation. It emphasizes that vaping-associated injury is not limited to the lungs and may manifest as a multi-system disease. Clinicians must maintain a high index of suspicion for EVALI and associated extrapulmonary complications like myopericarditis in patients, particularly young individuals, presenting with acute cardiorespiratory symptoms following vaping. A thorough history focusing on recent and past vaping habits (including product types, frequency, and any recent changes) is essential. Furthermore, a comprehensive cardiac assessment should be considered in all suspected EVALI cases, even when respiratory symptoms appear to dominate the clinical picture. This assessment should extend beyond basic vital signs to include cardiac biomarkers like troponin and NT-proBNP, electrocardiography, and transthoracic echocardiography. Early corticosteroid therapy and multidisciplinary management may improve outcomes, while continued public-health measures are vital to curb vaping among youth. Acknowledgements Not applicable. Abbreviations Acid-fast bacillus Acute Respiratory Distress Syndrome Colony-forming unit Chest X-ray E-cigarette, or vape-associated lung injury Intensive Care Unit Left-ventricular ejection fraction PaO₂/FiO₂ ratio Propylene glycol Polymerase chain reaction Respiratory syncytial virus Sudden cardiac arrest Tetrahydrocannabinol Vitamin E acetate Vegetable glycerin Authors’ contributions All authors have read and approved the manuscript, and significantly contributed to this paper. HDBT, QKTL, HMA, KLT, LLTT, TTNP: Conception and design, literature review, manuscript writing and correction, final approval of the manuscript. Funding No funding sources were used. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This manuscript was written in compliance with the ethical standards of the institutional ethics committee and with the Helsinki Declaration. Consent for publication Written informed consent was obtained from the patient’s parent/legal guardian (mother) for publication of this case report and any accompanying images, as the patient is a minor. A copy of the written consent is available for review by the Editor of this journal. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.